Cabaletta Bio
Engineered T cell therapies designed for the treatment of patients with autoimmune diseases
191 employees · est. 2017 · Philadelphia, United States
Connect Biopharma
Global Clinical Stage Company Connecting Patients with Innovation for Life
30 employees · est. 2012 · San Diego, United States
Connect Biopharma is the older company (2017 vs 2012); Cabaletta Bio is the larger of the two.
Side-by-Side Comparison
| Metric | Cabaletta Bio | Connect Biopharma |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2012 older |
| Headquarters | ||
| Headquarters | Philadelphia, United States | San Diego, United States |
| Employees | ||
| Employees | 191 larger | 30 |
| Industry | ||
| Industry | Biotechnology, Pharmaceutical | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | IPO | Series C |
| Total Funding | ||
| Total Funding | $322.00M | $195.00M |
| Funding Rounds | ||
| Funding Rounds | 8 | 4 |
| Services | ||
| Services | Development of T cell therapies for autoimmune diseases, Conducting Phase 1/2 clinical trials, CD19 chimeric antigen receptor T cell therapy development, Research and development of CABA® platform | Development of therapeutics for inflammatory diseases, Clinical trials for asthma and COPD treatments, Research on new mechanisms of action |
| Target Customers | ||
| Target Customers | Patients with autoimmune diseases, Healthcare providers specializing in rheumatology, dermatology, and neurology, Biotechnology researchers and collaborators, Investors in biopharmaceuticals | Patients with asthma, Patients with COPD, Healthcare professionals, Investors interested in biopharmaceutical innovation |
| Taxonomy | ||
| Taxonomy | Engineered T Cell Therapies, Autoimmune Diseases, Clinical-stage, CARTA Strategy, CAART Strategy, B Cell-mediated Autoimmune Diseases, CD19-CAR T, Mucosal Pemphigus Vulgaris, MuSK Myasthenia Gravis, Chimeric Antigen Receptor, Autologous CAAR T Cells, Therapeutic Platform, Selective Targeting, Partnership With Penn | Clinical-stage Biopharmaceuticals, Chronic Inflammatory Diseases, T Cell-driven Research, Interleukin-4 Receptor Targeting, Sphingosine 1-phosphate Receptor Modulation, Ulcerative Colitis Treatment, Crohn's Disease Treatment, Histamine Receptor Antagonism, Atopic Dermatitis Treatment, Global Clinical Development, Autoimmune Disease Therapies, In-house Drug Discovery, In-licensing Drug Candidates, Contract Research Organizations |
| Website | ||
| Website | cabalettabio.com | connectbiopharm.com |
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is at the forefront of innovation within the biotechnology sector, focusing on engineered T cell therapies aimed at treating autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, PA, this clinical-stage company is pioneering potentially curative medical...
About Connect Biopharma
Connect Biopharma Holdings Limited, founded in 2012, is a promising global clinical-stage biopharmaceutical company, emphasizing innovative therapies for chronic inflammatory diseases. The company's slogan, "Global Clinical Stage Company Connecting Patients with Innovation for Life," reflects its mi...
We will tell you when either one moves
BounceWatch watches Cabaletta Bio and Connect Biopharma for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Cabaletta Bio and Connect Biopharma — by email.
Frequently Asked Questions
Compare Cabaletta Bio with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Cabaletta Bio on 9 Jun 2026, and Connect Biopharma on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
